Efficacy of using a standard activity of 131I-MIBG therapy in patients with disseminated neuroendocrine tumours

Purpose The aim of this analysis was to evaluate the response to standard activity of 131I-meta-iodobenzylguanidine (MIBG) in patients with disseminated neuroendocrine tumours (NETs), comparing overall survival of patients with symptomatic response, tumour size (as assessed by CT) and relevant plasma tumour markers.